1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer incidence
4.2.2. Growing Adoption of Immunotherapy Over Other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry insights
5.1. Key industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. OPDIVO and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles (Overview, Products and Services, Financials, and Developments)
11.1. AstraZeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis Ag
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Major Cancer Immunotherapy Drugs Approved (2015–2017)
Table 2 Recent Developments for Cancer Immunotherapy Market in China
Table 3 Global Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 4 Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 5 Key Monoclonal Antibodies Approved for Cancer Immunotherapy
Table 6 Key Conjugated Antibodies for Cancer Immunotherapy
Table 7 Monoclonal Antibodies Market Size, by Country/Region, 2016–2024 ($Million)
Table 8 Major FDA Approved Pd-1 and Pd-L1 inhibitors
Table 9 Checkpoint inhibitors Market Size, by Country/Region, 2016–2024 ($Million)
Table 10 Key Immunomodulators Available in The Market
Table 11 Immunomodulators Market Size, by Country/Region, 2016–2024 ($Million)
Table 12 Cancer Vaccines Market Size, by Country/Region, 2016–2024 ($Million)
Table 13 Cell Therapies Market Size, by Country/Region, 2016–2024 ($Million)
Table 14 Global Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 15 Lung Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 16 Breast Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 17 Colorectal Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 18 Melanoma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 19 Prostate Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 20 Multiple Myeloma: Recent Developments from Leading Players
Table 21 Multiple Myeloma Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 22 Other Cancer Immunotherapy Market Size, by Country/Region, 2016–2024 ($Million)
Table 23 Global Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 24 Cancer Immunotherapy Market Size for Hospitals, by Country/Region, 2016–2024 ($Million)
Table 25 Cancer Immunotherapy Market Size for Clinics and Others, by Country/Region, 2016–2024 ($Million)
Table 26 North America: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 27 North America: Market Size, by Type, 2016–2024 ($Million)
Table 28 North America: Market Size, by Application, 2016–2024 ($Million)
Table 29 North America: Market Size, by End User, 2016–2024 ($Million)
Table 30 Leading Sites of New Cancer Cases (2017)
Table 31 U.S.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 32 U.S.: Market Size, by Application, 2016–2024 ($Million)
Table 33 U.S.: Market Size, by End User, 2016–2024 ($Million)
Table 34 Canada: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 35 Canada: Market Size, by Application, 2016–2024 ($Million)
Table 36 Canada: Market Size, by End User, 2016–2024 ($Million)
Table 37 Europe: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 38 Europe: Market Size, by Type, 2016–2024 ($Million)
Table 39 Europe: Market Size, by Application, 2016–2024 ($Million)
Table 40 Europe: Market Size, by End User, 2016–2024 ($Million)
Table 41 Germany: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 42 Germany: Market Size, by Application, 2016–2024 ($Million)
Table 43 Germany: Market Size, by End User, 2016–2024 ($Million)
Table 44 France: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 45 France: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 46 France: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 47 U.K.: Funding by National Cancer Research institute, 2012
Table 48 U.K.: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 49 U.K.: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 50 U.K.: Cancer Immunotherapy MarketSize, by End User, 2016–2024 ($Million)
Table 51 Italy: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 52 Italy: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 53 Italy: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 54 Spain: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 55 Spain: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 56 Spain: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 57 Rest of Europe: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 58 Rest of Europe: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 59 Rest of Europe: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 60 Asia Pacific: Cancer Immunotherapy Market Size, by Country, 2016–2024 ($Million)
Table 61 Asia Pacific: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 62 Asia Pacific: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 63 Asia Pacific: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 64 China: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 65 China: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 66 China: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 67 Japan: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 68 Japan: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 69 Japan: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 70 India: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 71 India: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 72 India: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 73 Rest of APAC: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 74 Rest of APAC: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 75 Rest of APAC: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 76 Latin America: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 77 Latin America: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 78 Latin America: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 79 Middle East and Africa: Cancer Immunotherapy Market Size, by Type, 2016–2024 ($Million)
Table 80 Middle East and Africa: Cancer Immunotherapy Market Size, by Application, 2016–2024 ($Million)
Table 81 Middle East and Africa: Cancer Immunotherapy Market Size, by End User, 2016–2024 ($Million)
Table 82 Key Products: Monoclonal Antibodies
Table 83 Key Products: Checkpoint inhibitors
Table 84 Key Products: Immunomodulators
Table 85 Key Products: Vaccines
Table 86 Key Products: Cell Therapies
List of Figures
Figure 1 Key Stakeholders in The Cancer Immunotherapy Market
Figure 2 Research Process
Figure 3 Key Executives interviewed
Figure 4 Primary Research Techniques
Figure 5 Market Size Estimation
Figure 6 Global Cancer Immunotherapy Market, 2016–2024 ($ Million)
Figure 7 Cancer Immunotherapy Market: Global Market Outlook, by Type 2018 Vs. 2024
Figure 8 Cancer Immunotherapy Market: Global Market Outlook, by Application, 2018 Vs 2024
Figure 9 Cancer Immunotherapy Market: Global Market Outlook, by End User 2018 Vs. 2024
Figure 10 Asia Pacific Region Expected to Witness the Fastest Growth During the Forecast Period
Figure 11 Cancer Immunotherapy: Regional Market Outlook, 2018 Vs 2024
Figure 12 Market Overview: Cancer Immunotherapy Market
Figure 13 Global Cancer incidence and Mortality (2018)
Figure 14 Cancer Therapy Deals Distribution (2012-2016)
Figure 15 Clinical Trials Check Point inhibitors (2017)
Figure 16 R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
Figure 17 Cancer incidence by Region (2018)
Figure 18 Per Capita Healthcare Expenditure in Selected Emerging Countries ($)
Figure 19 Improvement in 5 Year Survival Rates: Personalized Immunotherapy
Figure 20 Biopharmaceutical Companies Are Committed to Advancing Personalized Medicines
Figure 21 Clinical Trials for Cancer Immunotherapy in Combination
Figure 22 OPDIVO (BMS) Vs Keytruda (Merck)
Figure 23 Distribution of Approved Monoclonal Antibody Drugs by indication
Figure 24 Number of Combination Studies for Pd-1/Pd-L1 Mab
Figure 25 Global Cancer Immunotherapy Market Size, by Application, 2018–2024 ($Million)
Figure 26 Lung Cancer Statistics (2018)
Figure 27 Pd-1 & Pd-L1: New Clinical Trials and Average Enrolment Per New Trial
Figure 28 Breast Cancer Statistics (2018)
Figure 29 Colorectal Cancer Statistics (2018)
Figure 30 Melanoma incidence Rate, 2016 (Per 100,000)
Figure 31 Prostate Cancer Statistics (2018)
Figure 32 Global Cancer Immunotherapy Market, by End User, 2018–2024 ($Million)
Figure 33 U.S. Healthcare Spending ($ Billion)
Figure 34 U.S. Healthcare Spending ($ Billion)
Figure 35 U.S.: Country Health Profile (Cancer)
Figure 36 Canada: Cancer incidence by Type (2015)
Figure 37 Canada: Geriatric Population (Million)
Figure 38 Canada: Country Profile (Cancer)
Figure 39 Europe: Highest Share of Geriatric Population, 2010-2017
Figure 40 Germany: Country Health Profile (Cancer)
Figure 41 France: Country Health Profile
Figure 42 U.K.: Country Health Profile
Figure 43 Italy: Country Health Profile
Figure 44 Spain: Share of Clinical Trials in Oncology
Figure 45 Spain: Country Health Profile
Figure 46 Rest of Europe: Key indicators
Figure 47 China: Clinical Trials (2012–2016)
Figure 48 China: Country Health Profile
Figure 49 Japan: Country Health Profile
Figure 50 India: Country Health Profile
Figure 51 Australia: Country Health Profile
Figure 52 Brazil: Country Health Profile
Figure 53 Key Strategies Adopted by Major Players in The Market: Approvals
Figure 54 Market Share Analysis (2017)
Figure 55 Cancer Immunotherapy: Competitive Benchmarking
COVID-19
We are in the phase of updating this report by analysing the impact of COVID-19 on this market.
